Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $30.1 million.

  • Zentalis Pharmaceuticals' Accumulated Expenses fell 3543.22% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 3543.22%. This contributed to the annual value of $45.3 million for FY2024, which is 1681.45% down from last year.
  • Zentalis Pharmaceuticals' Accumulated Expenses amounted to $30.1 million in Q3 2025, which was down 3543.22% from $35.3 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Accumulated Expenses peaked at $54.4 million during Q4 2023, and registered a low of $30.1 million during Q3 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Accumulated Expenses averaged around $41.9 million, with its median value being $44.2 million (2022).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Accumulated Expenses skyrocketed by 4359.21% in 2023 and then tumbled by 3543.22% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Accumulated Expenses (Quarter) stood at $45.4 million in 2022, then grew by 19.91% to $54.4 million in 2023, then dropped by 16.81% to $45.3 million in 2024, then crashed by 33.45% to $30.1 million in 2025.
  • Its Accumulated Expenses stands at $30.1 million for Q3 2025, versus $35.3 million for Q2 2025 and $41.7 million for Q1 2025.